For research use only. Not for therapeutic Use.
DNDI-6174 is a cytochrome bc1 complex inhibitor with potent in vitro activity against a variety of Leishmania species. DNDI-6174 can reduce parasite burden in animal models of infection[1].
| Catalog Number | I040150 |
| CAS Number | 2868298-43-3 |
| Synonyms | 7-(2-amino-4,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-1,3-benzodioxole-4-carbonitrile |
| Molecular Formula | C16H13N5O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C16H13N5O2/c1-7-11(12-8(2)20-16(18)21-15(12)19-7)10-4-3-9(5-17)13-14(10)23-6-22-13/h3-4H,6H2,1-2H3,(H3,18,19,20,21) |
| InChIKey | UFCPCEFCXDROHW-UHFFFAOYSA-N |
| SMILES | CC1=C(C2=C(N=C(N=C2N1)N)C)C3=C4C(=C(C=C3)C#N)OCO4 |
| Reference | [1]. Stéphanie Braillard, et al. DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc1. Sci Transl Med. 2023 Dec 13;15(726):eadh9902. |
